PhotoPharmics is a clinical-stage therapeutic device company developing next-generation treatments for addressing neurodegenerative disorders through the eyes. We have 30+ years of research and experience in specialized phototherapy. We previously developed specialized solutions now widely used to regulate circadian rhythms for seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).

We are currently extending our research into several other neurodegenerative diseases. We aim to make a clinically meaningful difference in patients’ lives by delivering safe and effective treatments.

PhotoPharmics is privately held. Investors, inquire here.